Published: 2022 December 30

Hepatocellular Carcinoma Market Size, Competitive Landscape and Market Forecast - 2030

SKU : PH363
180 pages
Report Summary
Table of Contents
List of Tables & Figures

Hepatocellular Carcinoma Market is segmented by Treatment (Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery, Others), By End-User (Hospitals, Cancer rehabilitation centers, Clinics, Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030


Hepatocellular Carcinoma Market Overview

Hepatocellular Carcinoma Market size was valued at US$ YY million in 2022 and is estimated to reach US$ YY million by 2030, growing at a CAGR of 12.4% during the forecast period (2023-2030).

Hepatocellular carcinoma (HCC) is a typical type of preceding liver cancer than any other type of liver cancer. Hepatocellular carcinoma is usually diagnosed in people with chronic liver diseases, such as cirrhosis caused by hepatitis B or hepatitis C.

Hepatocellular Carcinoma Market - Strategic Insights



Market CAGR


Segments Covered

By Diagnosis Type, By Treatment Type, By End Users, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America


To Get a Free Sample Click here


Hepatocellular Carcinoma Market Dynamics

The availability of novel drugs, a strong pipeline basis, and growing efforts for early diagnosis will drive the HCC market

The growing efforts for early diagnosis of HCC drive global market growth.

The increasing efforts for early diagnosis of hepatocellular carcinoma are majorly driving the global market growth. For instance, the American Association for the Study of Liver Diseases recommends HCC screening in at-risk patients, including those with cirrhosis. Several studies have highlighted the strong association between HCC screening and improved early HCC detection, curative treatment and reduced HCC-related mortality. Furthermore, there are few clinical trials active to establish hepatocellular carcinomas diagnosis method, such as a study for evaluation of diagnostic accuracy of Contrast-Enhanced Ultrasound (CEUS) and Gadoxetic Acid-enhanced Liver MRI for diagnosis of hepatocellular carcinoma in patients with liver cirrhosis, a prospective, multicenter comparison study of multiphase contrast-enhanced CT and multiphase contrast-enhanced MRI for diagnosis of hepatocellular carcinoma and liver transplant allocation sponsored by American College of Radiology Imaging Network and a study to establish clinical feasibility of abbreviated MR protocol for HCC surveillance in the high-risk group which is estimated to be completed by August 2022.

The lack of diagnosis methods and treatment side effects restraining the global market growth.

However, the lack of accurate diagnosis methods, which makes it necessary to perform diagnosis repeatedly, increasing the financial burden on the patient and the side effects of the treatment, are hampering the global market growth.

COVID-19 Impact on Hepatocellular Carcinoma Market

The COVID-19 pandemic has transformed healthcare priorities which adversely impacted cancer management. A survey conducted by the NIH among 27 hospitals from 14 Asia-Pacific nations gathering hospital-level data on the number of recently diagnosed HCC cases during a pre-pandemic period and for the same period during the pandemic, it was observed that there was a reduction of around 27.3% in face-to-face patient consultations and an upsurge of nearly 18.3% in video/telephonic consultations during the pandemic. A significant variation in changes in HCC management was observed among countries. However, the impact differs according to the disease stage and country; well-planned long-term approaches are needed to eliminate the negative consequence of the pandemic on HCC patients.

Hepatocellular Carcinoma Market Segment Analysis

Chemotherapy is expected to have a greater grasp of the hepatocellular carcinoma market during the forecast period (2022-2029)

Chemotherapy is dominating the global market and is predicted to dominate throughout the forecast period (2022-2029) owing to a large number of active interventional clinical studies, according to the around 18 studies are active and are expected to be completed during the forecast period examples of a few are a Phase 3 study to estimate the safety and efficacy of the Hepatic Arterial Infusion Chemotherapy Plus Sorafenib Compared With Transarterial Chemoembolization Plus Sorafenib in Patients With BCLC C Stage Hepatocellular Carcinoma sponsored by Sun Yat-sen University and a Research on Effectiveness and Safety of the Treatment, Hyperthermic Intraperitoneal Chemotherapy Combined With Tislelizumab and Targeted Therapy, That is Used for High-risk Hepatocellular Carcinoma After R0 Resection sponsored by the Sulai Liu, Hunan Provincial People's Hospital and is predicted to be completed by July 2025.

Moreover, the increasing cases of hepatocellular carcinoma are contributing to the dominance of chemotherapy in the global market. According to the World Cancer Observatory, over 905677 new liver cancer cases were diagnosed in 2020, and as per the Cleveland Clinic, hepatocellular carcinoma accounts for about 85%-90% of all primary liver cancers.

Geographical Analysis

North America is expected to command dominating the global hepatocellular carcinoma market.

North America dominate the global hepatocellular carcinoma market and is expected to show a similar trend throughout the forecast period (2022-2029) owing to the high prevalence in this region, for instance, the American Cancer Society estimated that over 41,260 new cases would be diagnosed and around 30,520 deaths will be reported under primary liver cancer and intrahepatic bile duct cancer by the end of 2022. Furthermore, most of the key market players are U.S.-based, holding a large market share through different market strategies such as product launches, collaborations, acquisitions, partnerships, Etc, to ensure North America's dominance over the global market. For example, Pfizer Inc, Eli Lilly and Company, Bristol-Mayers Squibb and Polaris Pharmaceuticals, Inc. (PPI). In October 05, 2022, Pfizer acquired Global Blood Therapeutics, Inc. (GBT), a biopharmaceutical company dedicated to discovering, developing, and delivering life-changing treatments. Also, in August 17, 2022, Bristol Myers Squibb acquired Turning Point Therapeutics, expanding its precision oncology portfolio.

Competitive Landscape

The key players operating in the global hepatocellular carcinoma market are Novartis AG, Pfizer Inc, Eli Lilly and Company, Bristol-Mayers Squibb, Teva Pharmaceutical Industries Ltd., Bayer AG, Polaris Pharmaceuticals, Inc. (PPI), Advacare, F. Hoffmann-La Roche Ltd and Creative diagnostics. The key players are embracing various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the growth of the hepatocellular carcinoma market globally. For instance, in December 22, 2021, Novartis acquired Gyroscope Therapeutics.

Teva Pharmaceutical Industries Ltd.


Teva Pharmaceuticals was founded in 1901, in Jerusalem. It is today among the top 15 pharmaceutical companies worldwide. Teva has over 3600 medicines in its product portfolio, with 37,000 employees working globally and 53 production sites globally.

Product Portfolio:

The product portfolio of Teva Pharmaceutical Industries Ltd. for hepatocellular carcinoma has SORAFENIB TEVA: Indicated to treat hepatocellular carcinoma that cannot be treated with surgery.

The global hepatocellular carcinoma report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Trending Topics

Merkel Cell Carcinoma Market

Basal Cell Carcinoma Treatment Market

Papillary Thyroid Carcinoma Treatment Market

Buy this report
Single User
Multiple User
Enterprise User
Proceed to Buy